Quick Answer
Tevogen Bio Holdings Inc. reported Operating Income Loss of -$26.14 million for the year ending 2025.
- Tevogen Bio Holdings Inc. showed an increase of +51.2% in Operating Income Loss from 2024 to 2025.
- This data is from Tevogen Bio Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$2.32 million | Q2 2023: -$2.18 million | Q3 2023: -$2.33 million | Q1 2024: -$29.52 million | Q2 2024: -$8.60 million | Q3 2024: -$6.09 million | Q1 2025: -$10.36 million | Q2 2025: -$5.44 million | Q3 2025: -$5.73 million.
- Over the full 3 years of available data (2023 to 2025), Tevogen Bio Holdings Inc.'s Operating Income Loss has declined by 195.6%.
- Historical annual values: Fiscal year 2025: -$26.14 million | Fiscal year 2024: -$53.56 million | Fiscal year 2023: -$8.84 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: